Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

INVESTOR ALERT - electroCore, Inc. (ECOR) - Bronstein, Gewirtz & Grossman, LLC Notifies of Class Action and Lead Deadline: November 25, 2019

ECOR

NEW YORK, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against electroCore, Inc. (“electroCore” or the “Company”) (NASDAQ: ECOR) and certain of its officers, on behalf of shareholders who purchased electroCore securities: (a) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s June 2018 initial public offering (“IPO” or the “Offering”) and/or (b) between June 22, 2018 and September 25, 2019, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/ecor.   

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: ((1) the Company’s lead product, gammaCore, did not enjoy any advantages over other acute treatments for migraines and episodic cluster headaches; (2) as a result, doctors and patients were unlikely to adopt gammaCore over existing treatments; (3) the Company’s voucher program was not effective to increase adoption of gammaCore; (4) the Company lacked sufficient resources to successfully commercialize gammaCore; (5) the Company’s business plan and strategy was not sustainable because electroCore lacked sufficient revenue to be profitable; (6) the Company’s product registry and efforts were ineffective to initiate reimbursement policies by commercial payors for gammaCore; (7) the lack of reimbursement would materially impact adoption and sales of gammaCore; and (8) as a result, electroCore’s public statements were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/ecor or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in electroCore you have until November 25, 2019 to request that the Court appoint you as lead plaintiff.  A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

Primary Logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today